Free Trial
NASDAQ:ARVN

Arvinas Q2 2024 Earnings Report

Arvinas logo
$6.29 +0.05 (+0.80%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.34 +0.05 (+0.81%)
As of 08/8/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas EPS Results

Actual EPS
-$0.49
Consensus EPS
-$1.08
Beat/Miss
Beat by +$0.59
One Year Ago EPS
-$1.25

Arvinas Revenue Results

Actual Revenue
$76.50 million
Expected Revenue
$33.27 million
Beat/Miss
Beat by +$43.23 million
YoY Revenue Growth
+40.40%

Arvinas Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, July 30, 2024
Conference Call Time
7:00AM ET

Arvinas Earnings Headlines

Oppenheimer Remains a Hold on Arvinas Holding Company (ARVN)
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim
See More Arvinas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email.

About Arvinas

Arvinas (NASDAQ:ARVN), a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

View Arvinas Profile

More Earnings Resources from MarketBeat